WallStSmart

Broadcom Inc (AVGO)vsCommScope Holding Company, Inc. (VISN)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

Broadcom Inc generates 3645% more annual revenue ($75.46B vs $2.02B). VISN leads profitability with a 347.7% profit margin vs 38.9%. AVGO appears more attractively valued with a PEG of 0.43. AVGO earns a higher WallStSmart Score of 80/100 (A-).

AVGO

Exceptional Buy

80

out of 100

Grade: A-

Growth: 10.0Profit: 9.5Value: 5.7Quality: 7.0
Piotroski: 6/9Altman Z: 1.59

VISN

Strong Buy

74

out of 100

Grade: B

Growth: 6.7Profit: 6.5Value: 5.0Quality: 7.0
Piotroski: 5/9Altman Z: 0.34

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

AVGO6 strengths · Avg: 10.0/10
Market CapQuality
$1.89T10/10

Mega-cap, among the largest globally

PEG RatioValuation
0.4310/10

Growing faster than its price suggests

Return on EquityProfitability
33.4%10/10

Every $100 of equity generates 33 in profit

Profit MarginProfitability
38.9%10/10

Keeps 39 of every $100 in revenue as profit

Operating MarginProfitability
49.0%10/10

Strong operational efficiency at 49.0%

Revenue GrowthGrowth
47.9%10/10

Revenue surging 47.9% year-over-year

VISN6 strengths · Avg: 9.3/10
Price/BookValuation
0.6x10/10

Reasonable price relative to book value

Profit MarginProfitability
347.7%10/10

Keeps 348 of every $100 in revenue as profit

EPS GrowthGrowth
704.0%10/10

Earnings expanding 704.0% YoY

Debt/EquityHealth
0.0110/10

Conservative balance sheet, low leverage

P/E RatioValuation
17.4x8/10

Attractively priced relative to earnings

Revenue GrowthGrowth
21.6%8/10

Revenue surging 21.6% year-over-year

Areas to Watch

AVGO3 concerns · Avg: 2.7/10
Altman Z-ScoreHealth
1.594/10

Distress zone — elevated risk

P/E RatioValuation
66.3x2/10

Premium valuation, high expectations priced in

Price/BookValuation
20.1x2/10

Trading at 20.1x book value

VISN3 concerns · Avg: 2.0/10
PEG RatioValuation
2.942/10

Expensive relative to growth rate

Free Cash FlowQuality
$-228.80M2/10

Negative free cash flow — burning cash

Altman Z-ScoreHealth
0.342/10

Distress zone — elevated risk

Comparative Analysis Report

WallStSmart Research

Bull Case : AVGO

The strongest argument for AVGO centers on Market Cap, PEG Ratio, Return on Equity. Profitability is solid with margins at 38.9% and operating margin at 49.0%. Revenue growth of 47.9% demonstrates continued momentum.

Bull Case : VISN

The strongest argument for VISN centers on Price/Book, Profit Margin, EPS Growth. Profitability is solid with margins at 347.7% and operating margin at 7.1%. Revenue growth of 21.6% demonstrates continued momentum.

Bear Case : AVGO

The primary concerns for AVGO are Altman Z-Score, P/E Ratio, Price/Book. A P/E of 66.3x leaves little room for execution misses.

Bear Case : VISN

The primary concerns for VISN are PEG Ratio, Free Cash Flow, Altman Z-Score.

Key Dynamics to Monitor

VISN carries more volatility with a beta of 1.93 — expect wider price swings.

AVGO is growing revenue faster at 47.9% — sustainability is the question.

AVGO generates stronger free cash flow (10.3B), providing more financial flexibility.

Monitor SEMICONDUCTORS industry trends, competitive dynamics, and regulatory changes.

Bottom Line

AVGO scores higher overall (80/100 vs 74/100), backed by strong 38.9% margins and 47.9% revenue growth. Both earn "Exceptional Buy" and "Strong Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Broadcom Inc

TECHNOLOGY · SEMICONDUCTORS · USA

Broadcom Inc. is an American designer, developer, manufacturer and global supplier of a wide range of semiconductor and infrastructure software products. Broadcom's product offerings serve the data center, networking, software, broadband, wireless, and storage and industrial markets.

Visit Website →

CommScope Holding Company, Inc.

TECHNOLOGY · COMMUNICATION EQUIPMENT · USA

Gyroscope Therapeutics Holdings plc, a clinical-stage gene therapy company, develops gene therapy products to treat patients with eye diseases. The company is headquartered in Stevenage, the United Kingdom.

Want to dig deeper into these stocks?